Guangzhou Cellgene Biotechnology Co., Ltd (hereinafter referred to as Cellgene Bio) is an innovative private R&D and production company focusing on advanced medical and health technology, biopharmaceutical development and commercialization of scientific and research findings. The company exports high-tech R&D achievements and products to the pharmaceutical, diagnostic, and medical cosmetology industries. The company has a qualified consultant team, multiple recipients of National Outstanding Youth Foundation and multiple entrants of Thousand Youth Talents Plan. Guided by market demand, on the basis of its own R&D and innovation capabilities, our company organizes the linkage of production, learning, research and use, establishes an efficient resource integration and collaboration mechanism. Through the incubation and industrialization of high-tech, the company maximizes the value of research and development, and ultimately makes cutting-edge medical and health technologies serve the public better and faster.

Cellgene Bio employs more than ten professors from Sun Yat-sen University and Chinese Academy of Sciences as part-time technical consultants and 5 part-time sales staff.

At present, Cellgene Bio has signed cooperation agreements with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Zhongnan Hospital of Wuhan University, Wuhan University School of Nursing, Zibo Vocational Institute, Guangzhou Canton Biologics, Guangzhou Kairuiteng Biology, Guangdong Beating Origin and other companies, completed more than 2 million sales orders such as growth factors, exported more than 1 million natural products, and also participated in the transfer of a number of invention patents.

Several medical devices developed by Cellgene Bio have passed the performance verification and are currently undergoing corresponding registration.

In 2022, Cellgene Bio was approved for import and export qualification by China Customs, obtained Business license qualification for Class III medical devices, and was selected as a small and medium-sized sci-tech enterprises by Department of Science and Technology of Guangdong Province. At the same time, the company made strategic adjustments and new investors joined - Strategic cooperation between Wisetemp company (Russia), Senswork Company (Hong Kong), Nanjing Vazyme Company, Guangdong Efong Pharmaceutical, Wuhan United Pharmaceutical and other companies. It is expected that multiple products will be registered in the Commonwealth of Independent States, Malaysia, Indonesia and Hong Kong, and two medical device products transformed by the Russian National Academy of Sciences will be introduced.